Ibrutinib Trials Against SLL/CLL and MCL Complete Enrollment

Pharmacyclics is announcing that they have met their enrollment target of 350 patients for a Phase III study of ibrutinib monotherapy compared to ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL).

The so-called RESONATE trial is now officially closed to enrollment.

The primary endpoint will be to demonstrate a clinically significant improvement in progression-free survival (PFS) with ibrutinib compared to ofatumumab.

Depending on the interim analysis of data, the company may seek an early filing for the drug with the US Food and Drug Administration.

Said Maria Fardis, Chief of Oncology Operations and Alliances at Pharmacyclics:

In addition to our outstanding team, we are grateful to the patients, their treating physicians, and the clinical sites for their participation in our RESONATE study and their strong support of the ibrutinib program.

Additionally, Pharmacyclics has completed enrollment for a Phase II single-arm study using ibrutinib in patients with mantle cell lymphoma (MCL) whose disease has progressed following bortezomib therapy and have received at least one prior rituximab-containing chemotherapy regimen

The so-called SPARK global study will have as its primary endpoint overall response rate (ORR).

The company intends to file a New Drug Application (NDA) with the FDA for the use of ibrutinib in patients with relapsed or refractory MCL prior to year-end.

Ibrutinib is a drug that was designed specifically to target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK), a key mediator of as many as three critical B-cell pro-survival mechanisms: regulation of apoptosis, cell adhesion, and cell migration and homing.

Source: Pharmacyclics

More Articles

More Articles

Lymphoma patients may have the option to participate in clinical trials, gaining access to an experimental treatment before it is widely available...

Since there are several subtypes of T cell lymphoma, there will necessarily be several non-specific T cell lymphoma...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

After surviving lymphoma treatments, patients should be on the lookout for late effects. These are symptoms that arise well after treatment has...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...

The short answer: both. Let's begin with a simple definition of radiation: Radiation is the energy emitted from an energy source. That energy...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...